AstraZeneca deepens gene editing capabilities with Revvity partnershipR&D, TherapeuticsAstraZeneca inked a non-exclusive licensing agreement with Revvity for access to the Massachusetts biotech’s proprietary gene editing technology to develop cell therapies for cancer and immune-mediated conditions, Revvity announced Thursday. Read more May 18, 2023/by BioSpace https://www.pharmalive.com/wp-content/uploads/2023/05/medical-lab-medical-research.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2023-05-18 21:15:232023-05-19 10:17:05AstraZeneca deepens gene editing capabilities with Revvity partnership